about
Hepatitis B virus therapy: What's the future holding for us?Hepatitis B and Delta Virus: Advances on Studies about Interactions between the Two Viruses and the Infected HepatocyteAnti-HBV Drugs: Progress, Unmet Needs, and New HopeCurrent and future antiviral drug therapies of hepatitis B chronic infectionMicroRNAs as therapeutic strategy for hepatitis B virus-associated hepatocellular carcinoma: current status and future prospectsEncapsidated hepatitis B virus reverse transcriptase is poised on an ordered RNA latticeControl of hepatitis B virus replication by interferons and Toll-like receptor signaling pathwaysCyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP).Hydroxylated tropolones inhibit hepatitis B virus replication by blocking viral ribonuclease H activity.Search for a cure for chronic hepatitis B infection: How close are we?Inhibition of hepatitis B virus gene expression and replication by hepatocyte nuclear factor 6.Identification of Antiviral Agents Targeting Hepatitis B Virus Promoter from Extracts of Indonesian Marine Organisms by a Novel Cell-Based Screening Assay.Identification of hydrolyzable tannins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently closed circular DNA.Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation.Glutathione S-transferase P1 correlated with oxidative stress in hepatocellular carcinomaMolecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections.HBx Gene Mutations in Hepatitis B Virus and Hepatocellular Carcinoma.Hepatitis B virus: from immunobiology to immunotherapy.Current developments in nucleoside/nucleotide analogues for hepatitis B.Natural history of chronic hepatitis B virus infection.Recent advance of the hepatitis B virus inhibitors: a medicinal chemistry overview.T-cell responses in hepatitis B and C virus infection: similarities and differences.Reactive Oxygen Species-Mediated c-Jun NH2-Terminal Kinase Activation Contributes to Hepatitis B Virus X Protein-Induced Autophagy via Regulation of the Beclin-1/Bcl-2 Interaction.Full-length genomic sequence of hepatitis B virus genotype C2 isolated from a native Brazilian patient.The role of microRNAs in hepatocyte metabolism and hepatitis B virus replication.Interferon-Stimulated Gene 15 Conjugation Stimulates Hepatitis B Virus Production Independent of Type I Interferon Signaling Pathway In Vitro.Modulation of Wnt signaling pathway by hepatitis B virus.A Molecular Breadboard: Removal and Replacement of Subunits in an Hepatitis B Virus Capsid.Sodium taurocholate cotransporting polypeptide inhibition efficiently blocks hepatitis B virus spread in mice with a humanized liver.Development of magnetic capture hybridization and quantitative polymerase chain reaction for hepatitis B virus covalently closed circular DNA.Structurally similar woodchuck and human hepadnavirus core proteins have distinctly different temperature dependences of assembly.Nucleic Acid Sensors Involved in the Recognition of HBV in the Liver-Specific in vivo Transfection Mouse Models-Pattern Recognition Receptors and Sensors for HBVProtective Effects of Moringa oleifera on HBV Genotypes C and H Transiently Transfected Huh7 Cells.Design and synthesis of pyridine-pyrazole-sulfonate derivatives as potential anti-HBV agentsIP-10, p53, and Foxp3 Expression in Hepatocytes of Chronic Hepatitis B Patients with Cirrhosis and Hepatocellular CarcinomaIn Silico Analysis of Hepatitis B Virus Occult Associated Mutations in Botswana Using a Novel AlgorithmScreening for hepatitis D and PEG-Interferon over Tenofovir enhance general hepatitis control efforts in Brazil
P2860
Q26774198-F9666F7C-D771-4599-B1DD-2F1C9B34651AQ26775635-3995A4E0-8688-4242-96B7-40DBCB9BA9F6Q26782742-7CB4648A-4A4D-4E49-A7BC-10A3A0F11686Q28084820-503DD326-CF22-4B24-A3AE-351BD1D9B9F1Q33661037-03AA666E-F8E0-48D8-887A-8191646EB240Q34025364-E8FB366E-8A45-448E-81B0-83316F2B37F5Q34137297-598A3D15-2CF2-4A47-B016-C46CDF4160A6Q34693445-50599E85-4794-49ED-A6A7-AEFD0F0FC808Q35105877-B9826116-FF66-4E6C-9169-1BD1CD79C9A4Q35626790-32C3A39C-6F53-4DDB-94A6-D710A0E45988Q35640972-260D2759-6277-4F4D-83AA-E7DC6C38507DQ35839652-C90824AB-32C9-45C7-B7E8-F0AFD92FD9A9Q36122356-2C1D1C88-0FDE-4646-9791-79753429E955Q36287428-69F87F00-F87E-4B89-8B8F-E56103636850Q36746926-A58EAA76-567C-4ECC-B148-BCDB02B7B7A9Q37295260-998FADD5-941E-4187-8E1D-01C6AD7E27B1Q37311716-1D538E82-DB50-402C-AA9C-E7CF8A888762Q38046619-E9EA6B6B-55C3-4784-A8ED-039EF3238AE2Q38208628-0EE60F9E-16E1-4C91-B8C8-773C39F67CE7Q38300425-931F2886-F612-415E-BE41-2DA5A80D2444Q38447283-FDBD1115-F627-4F57-AAE3-6ECA655AE296Q38514244-498183F2-4D8D-47B5-B7B9-6EF2628E0F97Q38780065-D3765850-F64D-48B9-A23A-30D46FA95F1BQ38871218-AD39AEAF-43E1-440A-80C9-C714C939049CQ39072215-9F2C834B-716C-43D9-A20E-CB6BB71AD566Q39170332-47319A2F-5000-4928-957E-1FDFB175F262Q39419969-CC7ABE45-1172-4ADB-94AC-7AB9A48477F3Q40088212-DB686DC8-7508-468A-AB2E-00C302CAF97CQ40640234-9BEC8E5D-A8AF-468A-B5C0-20BBD15D2887Q41449217-0A16DF71-86AC-4F2E-9A2D-B4AC7CAC350CQ41607431-877B8C1E-5608-499C-A707-04ABB0FE64FBQ42705659-C7358F55-39A9-49BB-B1D3-6A6AFAE31F1FQ47131939-3AD5C458-FCFB-4DB4-AC7D-2E0F732E65E9Q57084513-E2B21BF2-C9A0-4584-AEAC-0CB2FC959034Q57931024-82A874C9-DC0D-4472-BC1B-3C77DDB57C6CQ58726310-274CC6D4-780F-4A9E-A127-AC454497B67EQ58759982-9FB61BB7-6C3E-4C37-B350-65EAD5B2AF6F
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
HBV life cycle and novel drug targets.
@en
HBV life cycle and novel drug targets.
@nl
type
label
HBV life cycle and novel drug targets.
@en
HBV life cycle and novel drug targets.
@nl
prefLabel
HBV life cycle and novel drug targets.
@en
HBV life cycle and novel drug targets.
@nl
P2093
P2860
P1476
HBV life cycle and novel drug targets.
@en
P2093
Daniel Grimm
Hubert E Blum
Robert Thimme
P2860
P2888
P304
P356
10.1007/S12072-011-9261-3
P577
2011-03-08T00:00:00Z